PFID-EUROPEAN-CHAPTER
Infections due to antimicrobial resistance (AMR) are a significant threat to modern healthcare as well as to public health. In Europe, 33,000 individuals are estimated to die every year as a result of an infection caused by antibiotic-resistant bacteria.1 The COVID-19 crisis reinforced the critical importance of treatments for infectious diseases, as many related deaths and severe cases involve not only the virus, but are also complicated by secondary bacterial infections.
AMR is a threat to all of us, especially those with chronic conditions. Without effective antibiotics, patients lose not just treatments for serious infections but also face significantly increased risks from many medical services that rely upon the effective prevention and treatment of infections. If no action is taken, drug-resistant diseases could cause 10 million deaths each year by 2050 and damage to the economy as catastrophic as the 2008-2009 global financial crisis. By 2030, antimicrobial resistance could force up to 24 million people into extreme poverty.
The Partnership to Fight Infectious Disease is launching in the EU to help prevent this crisis. The Partnership to Fight Infectious Disease EU’s (PFID) goal is to explore and advance solutions to combat the growing threat of AMR. PFID currently exists in the United States and Japan and is launching in the EU. PFID is a non-profit group of patients, providers, community organizations, academic researchers, business and labor groups, and infectious disease experts working to raise awareness of threats posed by infectious diseases. Dr. Ishii, a professor at the Institute of Medical Science, The University of Tokyo,“welcomes the establishment of the PFID chapter in Europe. Infectious diseases and antimicrobial resistance must be discussed internationally, and these discussions will lead to innovative solutions to solving this crisis on a global scale.”
The shortage of new antibiotics has two main causes. Firstly, the development of new and novel antibiotics to treat AMR infections is very scientifically challenging– the last novel class of antibiotics was approved in 19862. Secondly, the market for new antibiotics is not commercially sustainable. PFID seeks to address both of these by working with policymakers to ensure the environment is suitable for the amount of investment required.
“Ninety percent of AMR innovation comes from small companies, but we desperately need to find better ways to help these life-saving products reach patients before it’s too late," said Kevin Outterson, Executive Director, CARB-X and PFID US Advisory Board Member. "The time for action is now and the EU has a vast opportunity to bring global solutions to the increasing problems posed by AMR."
Partnership to Fight Infectious Disease is a group of patients, providers, community organizations, academic researchers, business and labor groups, and infectious disease experts working to raise awareness of threats posed by infectious disease, as well as advance solutions to ensure future pandemic preparedness. PFID is a not-for-profit NGO.
1 https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(18)30605-4/fulltext
2 https://www.sciencedirect.com/science/article/pii/S1369527419300190
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20221215005624/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Nissan and Infobip Achieve 200% Increase in Engagement with AI-Driven WhatsApp Campaign5.11.2025 10:00:00 CET | Press release
AI-powered voice game sets new standard for digital marketing Nissan has redefined customer engagement by partnering with global cloud communications platform Infobip to pioneer a first-of-its-kind Agentic AI campaign. Nissan Kingdom of Saudi Arabia (KSA) leveraged Infobip’s newly launched Conversational AI Gamification, an AI-powered toolset that enables playful, immersive experiences across messaging channels. The marketing campaign utilized Infobip's Vocalize feature, an AI-powered voice game where users competed to win a brand-new Nissan Magnite. Participants used their voices to match an audio waveform to the outline of a car, directly within WhatsApp. This innovative approach transformed lead generation into an engaging competition, driving user participation and brand interaction. For Nissan KSA, the campaign enhanced brand awareness, increased engagement time, simplified lead acquisition, and stronger brand affinity. The innovative format also provided a cost-effective acquisit
NHOA Energy Commissions a 50 MWh Energy Storage System in Sicily5.11.2025 08:45:00 CET | Press release
The Vicari BESS, supplied on a turnkey EPC basis, integrates advanced storage technologies with two of ERG’s onshore wind farms, strengthening Sicily’s role in Italy’s energy transition NHOA Energy, a global provider of utility-scale energy storage systems, announces the commissioning of a 50 MWh Battery Energy Storage System (BESS) in Vicari, Sicily. Developed for ERG, a leading international independent renewable power producer, this project marks a major milestone in the deployment of large-scale storage systems supporting grid stability and renewable energy integration. Located at ERG’s substation connected to the Vicari and Roccapalumba wind farms, the system has a power capacity of 12.5 MW and a nominal storage capacity of 50 MWh, enabling it to store renewable energy for up to four hours. Fully designed, built, and commissioned by NHOA Energy as both BESS supplier and EPC (Engineering, Procurement and Construction) contractor, the project integrates proprietary Power Conversion
Galderma Receives U.S. FDA Approval for Restylane® Lyft™ for the Enhancement of the Chin Profile5.11.2025 07:00:00 CET | Press release
This approval is based on results showing the safety and effectiveness of Restylane Lyft in enhancing the chin profile, with high patient satisfaction and long-lasting results1,2 Restylane Lyft is the only hyaluronic acid (HA) injectable approved to treat the midface, facial folds and wrinkles, back of hands and the chin, with consistent results observed across diverse patient types1,2 Galderma’s Restylane portfolio, including Restylane Lyft, is supported by decades of clinical evidence and real patient experiences with over 77 million treatments delivered worldwide3,4 Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Restylane Lyft with Lidocainefor augmentation of the chin region to improve the chin profile in patients over the age of 21 with mild-to-moderate chin retrusion.2 Restylane Lyft is a versatile HA injectable with over 20 years of worldwide safety data, which is also
The Estée Lauder Companies Announces Pricing of Secondary Offering of Class A Common Stock by Selling Stockholders5.11.2025 02:08:00 CET | Press release
The Estée Lauder Companies Inc. (NYSE: EL) today announces the pricing of the previously announced registered public offering (the “Offering”) of the Company’s Class A Common Stock, par value $.01 per share, by trusts affiliated with descendants of Leonard A. Lauder (the “Selling Stockholders”) at a price to the public of $90 per share. The Selling Stockholders will receive all of the proceeds from the Offering. The Company is not selling any shares of Class A Common Stock in the Offering and will not receive any proceeds from the Offering. The Offering is expected to close on November 6, 2025, subject to the satisfaction of customary closing conditions. The Selling Stockholders intend to use the proceeds of the Offering to assist with the settlement of Leonard A. Lauder’s estate, including to satisfy certain estate obligations such as estate taxes, debts and administration expenses. Based on shares outstanding as of October 23, 2025, following completion of the offering, members of th
The Earthshot Prize and 500 Global Announce Strategic Partnership to Advance Climate Innovation in Emerging Markets5.11.2025 01:01:00 CET | Press release
500 Global and The Earthshot Prize are partnering on an investment strategy to identify, support and scale climate solutions across Emerging Markets.Supporting three themes at the intersection of climate impact and commercial viability: AgTech, Clean Tech, and Nature Tech.The strategy was announced at The Earthshot Prize Summit in Rio De Janeiro ahead of the 2025 Earthshot Prize Awards Night, targeting to roll out H1 of 2026. 500 Global, one of the world’s most active venture capital firms and The Earthshot Prize, the world’s most prestigious and impactful environmental award, are announcing today a new strategic partnership to accelerate climate innovation in Emerging Markets, as climate finance is more relevant than ever before. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251104586243/en/ 500 Global intends to develop and implement an investment strategy designed to de-risk early-stage investments, unlocking private cap
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom